請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85561完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 鄭文芳(Wen-Fang Cheng) | |
| dc.contributor.author | Chia-Ying Wu | en |
| dc.contributor.author | 吳佳穎 | zh_TW |
| dc.date.accessioned | 2023-03-19T23:18:37Z | - |
| dc.date.copyright | 2022-07-13 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-07-05 | |
| dc.identifier.citation | Ahmed, N., & Stenvers, K. L. (2013). Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol, 3, 256. https://doi.org/10.3389/fonc.2013.00256 Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet, 143 Suppl 2, 59-78. https://doi.org/10.1002/ijgo.12614 Bernardi, D., Padoan, A., Ballin, A., Sartori, M., Manara, R., Scienza, R., Plebani, M., & Della Puppa, A. (2012). Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol, 107(2), 299-305. https://doi.org/10.1007/s11060-011-0762-7 Boisen, M. K., Madsen, C. V., Dehlendorff, C., Jakobsen, A., Johansen, J. S., & Steffensen, K. D. (2016). The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. Int J Gynecol Cancer, 26(8), 1390-1398. https://doi.org/10.1097/igc.0000000000000798 Bonifácio, V. D. B. (2020). Ovarian Cancer Biomarkers: Moving Forward in Early Detection. In J. Serpa (Ed.), Adv Exp Med Biol (Vol. 1219, pp. 355-363). Springer. https://doi.org/10.1007/978-3-030-34025-4_18 Chiang, Y. C., Lin, H. W., Chang, C. F., Chang, M. C., Fu, C. F., Chen, T. C., Hsieh, S. F., Chen, C. A., & Cheng, W. F. (2015). Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget, 6(37), 39740-39755. https://doi.org/10.18632/oncotarget.5469 Choudhuri, S., Sharma, C., Banerjee, A., Kumar, S., Kumar, L., & Singh, N. (2014). A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. Mol Cell Biochem, 386(1-2), 259-269. https://doi.org/10.1007/s11010-013-1863-8 Chudecka-Głaz, A., Górski, B., Zielińska, D., Błogowski, W., Wojciechowska, I., Bedner, R., & Rzepka-Górska, I. (2009). Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen. Eur J Gynaecol Oncol, 30(6), 668-671. Chudecka-Głaz, A. M., Cymbaluk-Płoska, A. A., Menkiszak, J. L., Sompolska-Rzechuła, A. M., Tołoczko-Grabarek, A. I., & Rzepka-Górska, I. A. (2014). Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res, 7, 62. https://doi.org/10.1186/1757-2215-7-62 Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., Cloven, N. G., Oaknin, A., DiSilvestro, P. A., Morgan, M. A., Nam, J. H., Leath, C. A., 3rd, Nicum, S., Hagemann, A. R., Littell, R. D., . . . Bookman, M. A. (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med, 381(25), 2403-2415. https://doi.org/10.1056/NEJMoa1909707 Corradi, M., Goldoni, M., Alinovi, R., Tiseo, M., Ampollini, L., Bonini, S., Carbognani, P., Casalini, A., & Mutti, A. (2013). YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Anticancer Res, 33(12), 5517-5524. Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., Clark, C. M., Quinn, J. F., D'Angelo, G., Malone, J. P., Townsend, R. R., Morris, J. C., Fagan, A. M., & Holtzman, D. M. (2010). YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry, 68(10), 903-912. https://doi.org/10.1016/j.biopsych.2010.08.025 Dönder, A., & Özdemir, H. H. (2021). Serum YKL-40 levels in patients with multiple sclerosis. Arq Neuropsiquiatr, 79(9), 795-798. https://doi.org/10.1590/0004-282x-anp-2020-0326 Dehn, H., Hogdall, E. V., Johansen, J. S., Jorgensen, M., Price, P. A., Engelholm, S. A., & Hogdall, C. K. (2003). Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand, 82(3), 287-293. https://doi.org/10.1034/j.1600-0412.2003.00010.x Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N., & Ducarme, G. (2019). Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res, 12(1), 28. https://doi.org/10.1186/s13048-019-0503-7 Dupont, J., Tanwar, M. K., Thaler, H. T., Fleisher, M., Kauff, N., Hensley, M. L., Sabbatini, P., Anderson, S., Aghajanian, C., Holland, E. C., & Spriggs, D. R. (2004). Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol, 22(16), 3330-3339. https://doi.org/10.1200/jco.2004.09.112 Faibish, M., Francescone, R., Bentley, B., Yan, W., & Shao, R. (2011). A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther, 10(5), 742-751. https://doi.org/10.1158/1535-7163.Mct-10-0868 Fuksiewicz, M., Kotowicz, B., Rutkowski, A., Achinger-Kawecka, J., Wagrodzki, M., & Kowalska, M. M. (2018). The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis. Technol Cancer Res Treat, 17, 1533033818765209. https://doi.org/10.1177/1533033818765209 González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., Baumann, K., Jardon, K., Redondo, A., Moore, R. G., Vulsteke, C., O'Cearbhaill, R. E., Lund, B., Backes, F., Barretina-Ginesta, P., . . . Monk, B. J. (2019). Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med, 381(25), 2391-2402. https://doi.org/10.1056/NEJMoa1910962 Gronlund, B., Høgdall, E. V., Christensen, I. J., Johansen, J. S., Nørgaard-Pedersen, B., Engelholm, S. A., & Høgdall, C. (2006). Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int J Biol Markers, 21(3), 141-148. Høgdall, E. V., Johansen, J. S., Kjaer, S. K., Price, P. A., Christensen, L., Blaakaer, J., Bock, J. E., Glud, E., & Høgdall, C. K. (2003). High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep, 10(5), 1535-1538. Hogdall, E. V., Ringsholt, M., Hogdall, C. K., Christensen, I. J., Johansen, J. S., Kjaer, S. K., Blaakaer, J., Ostenfeld-Moller, L., Price, P. A., & Christensen, L. H. (2009). YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer, 9, 8. https://doi.org/10.1186/1471-2407-9-8 Holst, C. B., Pedersen, H., Obara, E. A. A., Vitting-Seerup, K., Jensen, K. E., Skjøth-Rasmussen, J., Lund, E. L., Poulsen, H. S., Johansen, J. S., & Hamerlik, P. (2021). Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters. Cell Cycle, 20(7), 702-715. https://doi.org/10.1080/15384101.2021.1901037 Itik, V., Kemik, O., Kemik, A., Dulger, A. C., Sümer, A., Soyoral, Y. U., Begenik, H., Purisa, S., & Kotan, C. (2011). Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer, 3, 25-30. https://doi.org/10.4137/bic.S7154 Jensen, B. V., Johansen, J. S., & Price, P. A. (2003). High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res, 9(12), 4423-4434. Johansen, J. S., Schultz, N. A., & Jensen, B. V. (2009). Plasma YKL-40 a potential new cancer biomarker. Future Oncol., 5(7), 1065-1082. https://doi.org/10.2217/fon.09.66 Johansen, J. S., Schultz, N. A., & Jensen, B. V. (2009). Plasma YKL-40: a potential new cancer biomarker? Future Oncol, 5(7), 1065-1082. https://doi.org/10.2217/fon.09.66 Jonathan S. Berek, N. F. H. (2020). Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. In Berek and Hacker’s Gynecologic Oncology (7 ed., pp. p421-476). Wolters Kluwer. Kipps, E., Tan, D. S., & Kaye, S. B. (2013). Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer, 13(4), 273-282. https://doi.org/10.1038/nrc3432 Lakshmanan, M., Kumar, V., Chaturvedi, A., Misra, S., Gupta, S., Akhtar, N., Rajan, S., Jain, K., & Garg, S. (2019). Role of serum HE4 as a prognostic marker in carcinoma of the ovary. Indian J Cancer, 56(3), 216-221. https://doi.org/10.4103/ijc.IJC_305_18 Lin, H. W., Chiang, Y. C., Sun, N. Y., Chen, Y. L., Chang, C. F., Tai, Y. J., Chen, C. A., & Cheng, W. F. (2019). CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells. Endocr Relat Cancer, 26(1), 73-88. https://doi.org/10.1530/ERC-18-0300 Liu, K., Jin, M., Ye, S., & Yan, S. (2020). CHI3L1 promotes proliferation and improves sensitivity to cetuximab in colon cancer cells by down-regulating p53. J Clin Lab Anal, 34(1), e23026. https://doi.org/10.1002/jcla.23026 Luo, Z., Wang, Q., Lau, W. B., Lau, B., Xu, L., Zhao, L., Yang, H., Feng, M., Xuan, Y., Yang, Y., Lei, L., Wang, C., Yi, T., Zhao, X., Wei, Y., & Zhou, S. (2016). Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Lett, 377(2), 174-182. https://doi.org/10.1016/j.canlet.2016.04.038 Ma, B., Akosman, B., Kamle, S., Lee, C. M., He, C. H., Koo, J. S., Lee, C. G., & Elias, J. A. (2021). CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest, 131(21). https://doi.org/10.1172/jci137750 Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., Gourley, C., Banerjee, S., Oza, A., González-Martín, A., Aghajanian, C., Bradley, W., Mathews, C., Liu, J., Lowe, E. S., . . . DiSilvestro, P. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med, 379(26), 2495-2505. https://doi.org/10.1056/NEJMoa1810858 Muszyński, P., Groblewska, M., Kulczyńska-Przybik, A., Kułakowska, A., & Mroczko, B. (2017). YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease. Curr Neuropharmacol, 15(6), 906-917. https://doi.org/10.2174/1570159x15666170208124324 Prat, J. (2014). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet, 124(1), 1-5. https://doi.org/10.1016/j.ijgo.2013.10.001 Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alía, E. M., Reinthaller, A., Nagao, S., Lefeuvre-Plesse, C., Canzler, U., Scambia, G., . . . Harter, P. (2019). Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med, 381(25), 2416-2428. https://doi.org/10.1056/NEJMoa1911361 Rehli, M., Niller, H. H., Ammon, C., Langmann, S., Schwarzfischer, L., Andreesen, R., & Krause, S. W. (2003). Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem, 278(45), 44058-44067. https://doi.org/10.1074/jbc.M306792200 Robert J. Kurman, L. H. E., Brigitte M. Ronnett. (2019). Epithelial Tumors of the Ovary. In B. M. R. Jeffrey D. Seidman, Ie-Ming Shih, Kathleen R. Cho, and Robert J. Kurman (Ed.), Blaustein's Pathology of the Female Genital Tract (7th ed., pp. 841-966). Springer. https://doi.org/https://doi.org/10.1007/978-3-319-46334-6 Roslind, A., & Johansen, J. S. (2009). YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol, 511, 159-184. https://doi.org/10.1007/978-1-59745-447-6_7 Salani, R., Khanna, N., Frimer, M., Bristow, R. E., & Chen, L. M. (2017). An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol, 146(1), 3-10. https://doi.org/10.1016/j.ygyno.2017.03.022 Schultz, N. A., & Johansen, J. S. (2010). YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel), 2(3), 1453-1491. https://doi.org/10.3390/cancers2031453 Shao, R. (2013). YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol, 4, 122. https://doi.org/10.3389/fphys.2013.00122 Shao, R., Francescone, R., Ngernyuang, N., Bentley, B., Taylor, S. L., Moral, L., & Yan, W. (2014). Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis, 35(2), 373-382. https://doi.org/10.1093/carcin/bgt380 Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., & Yan, W. (2009). YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene, 28(50), 4456-4468. https://doi.org/10.1038/onc.2009.292 Stawerski, P., Wągrowska-Danilewicz, M., Stasikowska-Kanicka, O., & Danilewicz, M. (2011). Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol Res Pract, 207(9), 573-576. https://doi.org/10.1016/j.prp.2011.06.008 Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209-249. https://doi.org/10.3322/caac.21660 Tan, D. S. P., Agarwal, R., & Kaye, S. B. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet Oncology, 7(11), 925-934. https://doi.org/10.1016/s1470-2045(06)70939-1 Thorn, A. P., Daugaard, S., Christensen, L. H., Christensen, I. J., & Petersen, M. M. (2016). YKL-40 protein in osteosarcoma tumor tissue. Apmis, 124(6), 453-461. https://doi.org/10.1111/apm.12524 Wang, D., Zhai, B., Hu, F., Liu, C., Zhao, J., & Xu, J. (2012). High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One, 7(12), e51127. https://doi.org/10.1371/journal.pone.0051127 Watanabe, K., Shiga, K., Maeda, A., Harata, S., Yanagita, T., Suzuki, T., Ushigome, H., Maeda, Y., Hirokawa, T., Ogawa, R., Hara, M., Takahashi, H., Matsuo, Y., Mitsui, A., Kimura, M., & Takiguchi, S. (2022). Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer. Int J Oncol, 60(1). https://doi.org/10.3892/ijo.2021.5293 Yang, G. F., Cai, P. Y., Li, X. M., Deng, H. X., He, W. P., & Xie, D. (2009). Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng, 28(2), 142-145. Yu, J. E., Yeo, I. J., Son, D. J., Yun, J., Han, S. B., & Hong, J. T. (2021). Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization. Mol Oncol. https://doi.org/10.1002/1878-0261.13152 Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y. (2021). Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer, 1875(2), 188503. https://doi.org/10.1016/j.bbcan.2021.188503 Zhao, T., Su, Z., Li, Y., Zhang, X., & You, Q. (2020). Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther, 5(1), 201. https://doi.org/10.1038/s41392-020-00303-7 Zou, L., He, X., & Zhang, J. W. (2010). The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res, 43(12), 1232-1238. https://doi.org/10.1590/s0100-879x2010007500133 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85561 | - |
| dc.description.abstract | 背景：上皮性卵巢癌是全世界最致命的婦女癌症。大多數卵巢癌初次診斷時已是晚期(第三或第四期)，也就是腫瘤瀰漫在腹腔與骨盆腔，並且產生大量腹水。目前對於卵巢癌的標準治療是減積手術加上術後化學治療，但是卵巢癌往往在治療結束的兩年內復發。已經在許多慢性發炎疾病與癌症發現來自CHI3L1基因表現的YKL-40蛋白，本研究將分析上皮性卵巢癌患者腹水中的YKL-40量與患者臨床預後的關聯性。 研究方法：運用酵素免疫分析法Enzyme-linked immunosorbent assay (ELISA)衡量上皮性卵巢癌患者腹水中YKL-40含量，與患者臨床及病理表現的相關性。 結果：本研究收集150名卵巢癌患者。YKL-40含量與癌症期別、腹水是否發現腫瘤細胞、癌症復發，以及患者死亡相關。單變數分析中，高含量的YKL-40的患者其中位無病存活期(disease-free survival; DFS)較短(風險比：3.38，95%信賴區間：2.06−5.53，p<0.001)，患者的整體存活期(overall survival)較短(風險比：3.56，95%信賴區間：1.77−7.16，p<0.001)。多變數分析模式下，患者的整體存活期(overall survival)也較短(風險比：2.54，95%信賴區間：1.13−5.69，p=0.024)。漿液性腫瘤、癌症期別、腫瘤組織惡性度與YKL-40含量是影響預後的因子。 結論：卵巢癌晚期、惡性腹水、癌症復發，以及患者死亡，與YKL-40含量高相關。腹水中YKL-40含量是影響卵巢癌患者預後的因子。 | zh_TW |
| dc.description.abstract | Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancies all over the world. Most cases are diagnosed at advanced stages (stage III–IV) with disseminated intra-abdominal metastasis and ascites. The current standard treatment of ovarian cancer is surgery and adjuvant chemotherapy. While, disease recurrence occurs within 2 years. YKL-40, the product of CHI3L1 gene, is expressed in several human inflammation diseases or cancers. In the study, we measured the expression of YKL 40 in the ascites of EOC patients and evaluated if YKL-40 could be a prognostic factor of EOC patients. Methods: We then performed Enzyme-linked immunosorbent assay (ELISA) to evaluate the amount of YKL40 in the ascites of EOC patients. The correlation of YKL-40 expression and these clinic-pathologic parameters and the outcome of EOC patients were analyzed. Results: We first collected and stored the ascites of 150 EOC patients. The expression of YKL-40 in ascites of EOC patients were associated with advanced FIGO stage, positive ascites cytology, disease recurrence and disease-related death. Higher expression of YKL-40 in ascites of EOC patients were associated with shorter DFS (hazard ratio, 3.38; 95% confidence interval, 2.06-5.53; P < 0.001) and shorter OS (hazard ratio, 3.56; 95% confidence interval, 1.77-7.16; P < 0.001) by univariate analyses. By multivariate analyses. shorter OS (hazard ratio, 2.54; 95% confidence interval, 1.13-5.69; P = 0.024). Serous histology, FIGO stage, tumor grade, and the expression of YKL-40 are independent prognostic factors. Conclusions: EOC patients with advanced stage, malignant ascites, tumor recurrence and tumor-related death had significantly higher YKL-40 levels. YKL-40 in ascites was a prognostic factor for EOC patients. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T23:18:37Z (GMT). No. of bitstreams: 1 U0001-0407202209500200.pdf: 1299939 bytes, checksum: 065df084162fd5f89536667df461377a (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 目錄 誌謝...............................................................i 中文摘要(Abstract in Chinese).....................................ii 英文摘要(Abstract in English)....................................iii 第一章：緒論.......................................................1 第一節：上皮性卵巢癌................................................1 （一）上皮性卵巢癌的背景............................................1 （二）上皮性卵巢癌的診斷治療現況.....................................3 （三）卵巢癌的預後因子..............................................7 （四）YKL-40為具潛力的卵巢癌生物標記.................................8 第二節：研究的方向與目的............................................9 第二章：研究方法與材料.............................................10 第一節：上皮性卵巢癌患者資料與腹水來源...............................10 （一）上皮性卵巢癌患者及收集資料....................................10 （二）上皮性卵巢癌患者追蹤方式......................................11 （三）腹水檢體保存.................................................11 第二節：研究方法...................................................11 （一）酵素免疫分析法Enzyme-linked immunosorbent assay (ELISA).......11 （二）統計分析.....................................................12 第三章：結果.......................................................13 第一節：上皮性卵巢癌患者組成分析.....................................13 第二節：上皮性卵巢癌患者腹水中的YKL-40含量...........................13 第三節：上皮性卵巢癌患者存活率分析...................................15 第四節：上皮性卵巢癌患者術前CA125分析................................17 第四章：討論.......................................................21 第一節：建立新的卵巢癌預後指標-測量上皮性卵巢癌患者腹水YKL-40含量......21 第二節：YKL-40與卵巢癌.............................................21 第三節：YKL-40為具潛力的卵巢癌治療標的...............................23 （一）YKL-40的生理活動.............................................24 （二）YKL-40與血管新生.............................................24 （三）以YKL-40為治療工具...........................................26 第五章：展望.......................................................26 論文英文簡述.......................................................28 Chapter 1: INTRODUCTION...........................................28 Chapter 2: MATERIALS AND METHODS..................................29 Chapter 3: RESULTS................................................30 Chapter 4: DISCUSSION.............................................33 參考文獻...........................................................44 表目錄 Table 1 FIGO Ovarian cancer staging................................................36 Table 2 Clinicopathological characteristics of the 150 women with EOC..............37 Table 3 Mean expression levels of YKL-40 of the patients and subgroup analysis*....38 Table 4 Cox regression model for the risk factors for recurrence and death.........39 Table 5 Mean expression levels of CA125 of the patients and subgroup analysis......42 Table 6 Cox regression model of CA125 for the risk factors for recurrence and death..43 圖目錄 Figure 1 Disease free survival of the patients in different level of YKL-40.......40 Figure 2 Overall survival of the patients in different level of YKL-40............41 | |
| dc.language.iso | zh-TW | |
| dc.subject | CHI3L1 | zh_TW |
| dc.subject | YKL-40 | zh_TW |
| dc.subject | 卵巢癌 | zh_TW |
| dc.subject | 預後因子 | zh_TW |
| dc.subject | 腹水 | zh_TW |
| dc.subject | YKL-40 | en |
| dc.subject | CHI3L1 | en |
| dc.subject | ascites | en |
| dc.subject | prognostic factor | en |
| dc.subject | ovarian cancer | en |
| dc.title | 上皮性卵巢癌患者腹水YKL-40表現量與臨床預後的關聯性 | zh_TW |
| dc.title | Correlation of YKL-40 in Ascites and the Prognosis of Epithelial Ovarian Cancer Patients | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 江盈澄(Ying-Cheng Chiang) | |
| dc.contributor.oralexamcommittee | 林柏翰(Po-Han Lin) | |
| dc.subject.keyword | 卵巢癌,YKL-40,CHI3L1,預後因子,腹水, | zh_TW |
| dc.subject.keyword | ovarian cancer,YKL-40,CHI3L1,prognostic factor,ascites, | en |
| dc.relation.page | 53 | |
| dc.identifier.doi | 10.6342/NTU202201261 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2022-07-05 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-07-13 | - |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0407202209500200.pdf | 1.27 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。